Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

Urology

Volumn 55, Issue 5, 2000, Pages 639-642

  Fowler, Jackson E ^a   Flanagan, Michael ^b   Gleason, Donald M ^c   Klimberg, Ira W ^d   Gottesman, James E ^e   Shariei, Roohollah ^f  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b Seattle Urological Associates ^*  (United States)

^c University of Illinois School of Medicine ^*  (United States)

^d Ocala Orthopedic Group   (United States)

^e Seattle Urological Associates   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LEUPRORELIN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG IMPLANT; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PALLIATIVE THERAPY; PROSTATE TUMOR; TIME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG IMPLANTS; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 0034186059     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00479-9     Document Type: Article

References (6)

1. Moul JW: Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt) 12: 499-508, 1998.
2. Sharifi R, Soloway M, and the Leuprolide Study Group: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143: 68-71, 1990.
3. Akaza H, Usami M, Koiso K, et al: Long-term clinical study on luteinizing hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. Jpn J Clin Oncol 22: 177-184, 1992.
4. ShaheenJA, Amin M, and Harty JI: Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist. Urology 42: 533-535, 1993.
5. Fowler JE, Gottesman JE, Bardot SE, et al. DUROS™ leuprolide implantable therapeutic system in patients with advanced prostate cancer: 14-month results of a phase I/II dose-ranging study (abstract). J Urol 161: 300, 1999.
6. Sharifi R, Soloway M, Clayton M, et al: "Acute on chronic" effect of depot leuprolide in patients with stage D2 cancer of prostate. Anticancer Drugs 1: 29-31, 1990.